Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 21, 2025

Overcoming Key Operational Challenges in Integrating Bispecific Therapies

Experts discuss the most common logistical challenges encountered when implementing bispecific therapies as well as the primary barriers smaller community practices face in operationalizing bispecific antibody treatments.

Episodes in this series

EP. 1 Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

EP. 1 Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

3 experts are featured in this series.

EP. 2 Revolutionizing Cancer Treatment: Key Bispecific Antibody Approvals

3 experts are featured in this series.

EP. 3 How Bispecific Antibodies Are Reshaping Cancer Care

3 experts are featured in this series.

EP. 4 Optimizing Bispecific Antibody Use: Opportunities to Broaden Patient Access

3 experts are featured in this series.

EP. 5 Integrating Bispecific Antibodies in Community Oncology: Benefits and Considerations

3 experts are featured in this series.

EP. 6 Overcoming Key Operational Challenges in Integrating Bispecific Therapies

3 experts are featured in this series.

EP. 7 Partnerships in Bispecific Therapy: A Model for Supporting Community Oncology

3 experts are featured in this series.

EP. 8 Managing Complexity: Standardizing Workflows for Multiple Bispecific Therapies

3 experts are featured in this series.

EP. 9 Standardizing CRS Management and Ensuring Smooth Transitions of Care in Bispecific Therapy

3 experts are featured in this series.

EP. 10 Optimizing Bispecific Antibody Administration With EHR and Technology Solutions

3 experts are featured in this series.

EP. 11 Addressing Resource and Bandwidth Challenges in Bispecific Antibody Administration

3 experts are featured in this series.

EP. 12 Payer and Reimbursement Considerations for Bispecific Therapies

3 experts are featured in this series.

EP. 13 Emerging Therapeutic Areas for Bispecific Antibodies

3 experts are featured in this series.

EP. 14 Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities

3 experts are featured in this series.

EP. 15 Future Breakthroughs: What’s Next for Bispecific Antibodies in Oncology?

Video content above is prompted by the following:

What are the most common logistical challenges you encounter when implementing bispecific therapies?
What are the primary barriers that smaller community practices face in operationalizing bispecific antibody treatments?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Top view of red heart and medicine on wooden floor | Image credit: Jack Fotografo - stock.adobe.com

Acoramidis Shows Durable Benefit at 54 Months in ATTR-CM

ByPearl Steinzor

June 3rd 2026

3D image of heart failure | Image credit: appledesign - stock.adobe.com

Sudden Death in HFpEF Often Preceded by Clinical Decline

ByPearl Steinzor

June 3rd 2026

Community Advanced Therapy Access Drives Equity: Fran Gregory, PharmD

ByLaura Joszt, MA,Fran Gregory, PharmD, MBA

June 3rd 2026

FDA website | Image credit: Tada Images - stock.adobe.com

FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301

ByGiuliana Grossi

June 3rd 2026

CAR T Therapy Likely the Next Frontier for Treating Patients With MG: James F. Howard, MD

ByJulia Bonavitacola,James Howard, MD

June 2nd 2026

Trending on AJMC

FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301

New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease

Andes Hantavirus FAQs: What to Know as Quarantined Cruise Passengers Return Home

Cancer’s Hidden Wound: Trauma From Diagnosis Through Survivorship

Odronextamab Plus CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Matthew Matasar, MD